Furosemide group | Placebo group | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study (year) | Number of randomized patients | Number of patients completing study | Mean patient age (years) | Number of patients (male) | Mean patient age (years) | Number of patients (male) | Smoking | COPD | β-agonist dose | Inhaled furosemide dose | Expiratory airflow assessment time (minutes) | Spirometry measurement used | Severity | Hydrocortisone (mg) |
Alshehri and colleagues, 2005 [5] | 39 | 39 | 8.4 | 19 (11) | 8.5 | 20 (9) | N/Aa | N/Aa | 0.15 mg/kg | 1.0 mg/kg | 30 | PEFR, FEV1.0 | Moderate | N/A |
González-Sánchez and colleagues, 2002 [4] | 20 | 20 | 9.8 | 10 (7) | 10 | 10 (5) | N/Aa | N/Aa | 0.15 mg/kg | 1.0 mg/kg | 30, 60 | FEV1.0 | Mild or moderate | N/A |
Nannini and colleagues, 1992 [1] | 20 | 16 | 31 | 7 (N/A) | 41 | 9 (N/A) | N/A | N/A | 2.5 mg | 40 mg | 15, 30 | PEFR | N/A | N/A |
Nuhoğlu and colleagues, 2006 [3] | 32 | 32 | 8.6 | 16 (8) | 8.4 | 16 (12) | N/Aa | N/Aa | 0.15 mg/kg | 10 mg/m2 | N/A | PEFR | Mild or moderate | N/A |
Ono and colleagues, 1997b [6] | 37 | 37 | 47 | 20 (7) | 41 | 17 (8) | N/A | Exclude | N/A | 20 mg | 30, 60 | PEFR, FEV1.0 | Mild to severe | 100 |
Pendino and colleagues, 1998c [2] | 42 | 42 | 38 | 6 (N/A) | 34 | 8 (N/A) | Not >10 pack-years | Exclude | 2.5 mg | 40 mg | 15, 30 | PEFR | Mild or moderate | 300 |
Furosemide | Placebo | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PEFR | FEV1.0 | PEFR | FEV 1.0 | |||||||||||||
Study (year) | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD | Baseline airflow | SD | Post-treatment airflow | SD |
Alshehri and colleagues, 2005 [5] | 59.0 | 22.0 | 84.9 | 14.0 | 58.5 | 14.5 | 80.2 | 13.9 | 57.2 | 25.4 | 80.7 | 17.4 | 56.7 | 17.3 | 77.8 | 19.1 |
Nuhoğlu and colleagues, 2006 [3] | 178 | 65.9 | 222 | 66.1 | N/A | N/A | 183 | 51.7 | 218 | 60.3 | N/A | N/A | ||||
Baseline airflow
|
SD
|
Net airflow improvement above baseline
|
SD
|
Baseline airflow
|
SD
|
Net airflow improvement above baseline
|
SD
|
Baseline airflow
|
SD
|
Net airflow improvement above baseline
|
SD
|
Baseline airflow
|
SD
|
Net airflow improvement above baseline
|
SD
| |
González-Sánchez and colleagues, 2002 [4] | N/A | N/A | 0.820 | 0.460 | 0.910 | 0.067 | N/A | N/A | 0.850 | 0.340 | 0.980 | 0.078 | ||||
Nannini and colleagues, 1992 [1] | 147 | 68.0 | 269 | 89.7 | N/A | N/A | 234 | 82.0 | 316 | 56.2 | N/A | N/A | ||||
Ono and colleagues, 1997 [6] | 171 | 20.0 | 205 | 45.1 | 1.18 | 0.13 | 178 | 25.0 | 198 | 21.3 | 1.32 | 0.74 | N/A | |||
Pendino and colleagues, 1998 [2] | 200 | 71.0 | 426 | 98.0 | N/A | N/A | 209 | 68.0 | 337 | 73.2 | N/A | N/A |
Number of studies | Furosemide group ( n ) | Placebo group ( n ) | Lower 95% CI | Upper 95% CI | Z value | P value |
I
2
| |
---|---|---|---|---|---|---|---|---|
Whole studies | 6 | 78 | 79 | 0.14 | 0.85 | 2.70 | 0.007 | 16.8 |
PEFR | 5 | 68 | 70 | 0.058 | 0.90 | 2.23 | 0.026 | 30.4 |
FEV1.0 | 3 | 49 | 46 | -0.027 | 0.83 | 1.84 | 0.066 | 8.16 |